AAV Vector Resource
AAV serotype selection for nervous system research should be based on the target cell, brain region, promoter, delivery route, species, and study objective rather than serotype alone. Neurons, astrocytes, microglia, and oligodendrocytes differ in location and transduction requirements, so tissue- and cell-specific AAV targeting and promoter selection should be evaluated alongside AAV vector design. Matching these factors improves CNS targeting, expression specificity, and the interpretability of central nervous system gene therapy studies.
Direct Answer
Nervous system tissue is highly heterogeneous. Neurons, astrocytes, microglia, and oligodendrocytes differ in location, function, and the regulatory elements that drive their expression, so the first decision in AAV selection is which cell type you actually need to transduce.
Promoters are rarely "absolutely specific." Their expression range shifts with species, brain region, developmental stage, and delivery method, so high-specificity studies should combine literature evidence with experimental validation rather than relying on a promoter name alone.
The key principle: the useful question is not "which promoter for neurons?" but "which neuron subtype, in which region, in which model, with what expression range?"
hSyn and MeCP2 can support broad neuronal expression, while CaMKIIa is often used to enrich expression in forebrain excitatory neurons. Define the neuron subtype and projection field before selection, and confirm co-labeling with subtype markers rather than interpreting reporter signal alone as selectivity.
GFAP and the compact GfaABC1D element are used to favor astrocyte expression, but reactive state and anatomical region can alter the observed pattern. Compare reporter-positive astrocytes with neuronal and other glial populations in the same tissue sections.
MBP- and CNP-related elements can be considered when studying myelinating cells or their lineage. Define whether mature oligodendrocytes or precursor populations matter, then measure expression against stage-specific markers and white-matter distribution.
Standard AAV approaches often show limited microglial transduction, and a myeloid-active promoter alone cannot guarantee resident-microglia specificity. Pilot the capsid and cassette in the intended model, separating microglia from other CNS macrophages and infiltrating cells when disease alters the tissue.
Selection Mapping
Use the mapping to shortlist a capsid–promoter–route combination for a defined region and cell population. Compare candidates at matched dose and sampling time, then report both the fraction of target cells expressing the reporter and expression in adjacent or peripheral tissues.
| Target Cell | Representative Promoter | Typical Application | Key Caveat |
|---|---|---|---|
| Broad neurons | hSyn, MeCP2 | Neuronal expression, circuit tracing | Check neuronal-marker co-labeling and expression in adjacent glia within the actual region and species |
| Excitatory neurons | CaMKIIa | Forebrain excitatory neuron studies | Validate excitatory-subtype enrichment in the target circuit; promoter activity may vary with region and developmental stage |
| Astrocytes | GFAP, GfaABC1D | Glial biology, reactivity studies | Include reactive and baseline tissue states if disease changes GFAP activity or astrocyte distribution |
| Oligodendrocytes | MBP, CNP | Myelination and white-matter research | Differentiate precursors from mature myelinating oligodendrocytes with stage-specific markers |
| Microglia | Dedicated elements | Neuroinflammation studies | Pilot a microglia-directed capsid and regulatory element; distinguish resident microglia from other myeloid cells |
For cell-type-restricted expression, explore specific promoter-driven AAV targeting and tissue/cell-specific AAV vector services.
Design Logic
Working from the research goal outward—rather than from the serotype inward—keeps each variable aligned with the next.
Overexpression, knockdown, CRISPR, circuit tracing, or opto/chemogenetics?
Neuron subtype, astrocyte, microglia, or oligodendrocyte.
Match the regulatory element to the cell and desired range.
Combine serotype with model, region, and published data.
Local, CSF, or systemic delivery matched to the target region.
Key Variables
Treat capsid, promoter, payload, route, and host model as a linked design. A strong reporter signal has limited value unless its anatomical distribution and cell identity match the experiment, so compare candidates using the same dose, time point, and cell-resolved readout.
A promoter can shape expression only after the vector reaches the cell. Measure target-cell labeling and off-target expression in the same region, and repeat the check when disease state, age, or species changes.
Capsid performance depends on entry route and host biology as well as cell affinity. Compare candidates in the intended model with matched genome dose, then map regional coverage and target-cell fractions rather than relying on a single whole-brain signal.
After IV delivery, entry across the BBB can be strongly strain- and species-dependent; a mouse result does not establish NHP performance. Confirm the receptor and model context where relevant, and compare CNS signal with peripheral biodistribution before favoring a systemic route.
Budget the transgene together with promoter, regulatory elements, poly(A) sequence, and ITRs. Large editors or multicomponent tools may need a compact design or a different delivery strategy; verify the packaged genome rather than assuming that a short PCR amplicon proves full-length integrity.
scAAV can speed expression for small payloads but has substantially less usable cassette capacity. Decide between single-stranded and self-complementary formats after checking payload size, timing of the endpoint, and required expression level.
BBB receptor biology, regional anatomy, and route-dependent distribution can shift across mouse strains and species. Reconfirm the lead capsid–cassette combination in the model that will support the next decision, including peripheral exposure after systemic dosing.
Delivery Routes
Choose the route from the target region, desired spread, cell type, and acceptable peripheral exposure. The same vector can produce a different cell profile when delivered locally, into CSF, or intravenously; report anatomical coverage and dose together.
For region-specific studies: stereotactic delivery places vector close to the target nucleus or circuit and supports a defined injection site. Map spread around the track and distinguish local neuronal labeling from transduction along projecting axons.
For broader CNS delivery: ventricular dosing exposes CSF-facing structures and may distribute vector across multiple brain regions. Compare the intended region with ependymal and peripheral signal; age and capsid can change how much vector reaches parenchymal cells.
For CSF and spinal targets: intrathecal delivery places vector near the spinal cord and CSF compartment. Measure segmental coverage, dorsal-root-ganglion and brain exposure where relevant, and cell-type specificity before interpreting a motor-neuron endpoint.
For systemic exposure: IV administration can reach distributed sites but CNS entry depends on the capsid and host. Document brain and spinal-cord expression alongside liver and other peripheral tissues, especially when translating a mouse result to a different strain or species.
From Question to Evidence
Creative Biolabs can design, construct, and package the AAV that matches your nervous system target, from capsid selection through production and titration.
Define the target cell, region, perturbation, and readout before selecting capsid and regulatory elements. Build a cassette within AAV capacity and evaluate reporter expression in the intended model, distinguishing target-cell coverage from expression in neighboring neurons or glia.
Compare engineered or modified capsids by the intended route and host model, with matched genome dose and a reference vector. Assess CNS entry, region-specific expression, and peripheral biodistribution; combine capsid selection with promoter control when cell-type restriction is required.
Produce and purify the selected capsid–cassette combination at a concentration and volume suited to local, CSF, or systemic study plans. Review lot identity, genome titer, purity, and formulation before assigning material to animals, and keep handling conditions consistent across cohorts.
Measure genome concentration with a defined qPCR or ddPCR assay and include a relevant transduction readout when activity matters. Record vg per animal or injection site, administered volume, and assay method so dose-response and lot comparisons remain interpretable.
Review available recombinant AAV products when the existing capsid, promoter, and payload fit the study objective. Confirm the supplied quality data and compatibility with the target region, cell class, delivery route, and sampling schedule before selecting a catalog vector.
Selected Reading
Chan KY, Jang MJ, Yoo BB, et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017;20(8):1172-1179. https://doi.org/10.1038/nn.4593.
Tervo DGR, Hwang BY, Viswanathan S, et al. A designer AAV variant permits efficient retrograde access to projection neurons. Neuron. 2016;92(2):372-382. https://doi.org/10.1016/j.neuron.2016.09.021.
Watakabe A, et al. Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci Res. 2015;93:144-157. https://doi.org/10.1016/j.neures.2014.09.002.
FAQ
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
